Coherus Oncology Cuts 30% of Workforce

The biopharmaceutical company is reducing headcount from about 140 to 100 full-time employees as it narrows its clinical pipeline.

Updated on Nov. 10, 2026 in Nursing Jobs

Clean vector editorial illustration of unlabeled glass vials and a flask on a flat lab bench, one vial partly emptied, in cool slate and cream tones.
Coherus Oncology will cut about 30% of its workforce, trimming roughly 140 full-time employees to 100 while narrowing its tagmokitug trial toward second-line esophageal cancer. AI Illustration. Upload story photo >

Coherus Oncology announced a 30% workforce reduction to lower operating expenses, following its exit from the biosimilar business. The company is also narrowing tagmokitug clinical development toward second-line esophageal cancer.

Why it matters

The cuts are intended to streamline operations and reduce quarterly costs by $6 million to $7 million. The restructuring reflects a shift in focus toward its oncology products and a faster potential regulatory path for tagmokitug.

Coherus reported $14 million in LOQTORZI third quarter net sales, up 25% year-over-year, while the workforce cut is expected to save $6 million to $7 million per quarter. Reaching core cash breakeven will require $25 million to $30 million in quarterly revenue, a level the company has not yet disclosed reaching.

The players

Coherus Oncology

A biopharmaceutical company focused on oncology therapies, including the immuno-oncology drug LOQTORZI, which it markets in the United States.

The details

The workforce reduction is taking place this month, moving the company from roughly 140 to 100 full-time employees. Tagmokitug, combined with toripalimab, showed responses in both main tumor cell types, and the go-forward dose is 700 milligrams.

Timeline

  1. Nov. 9, 2026: Coherus held its third quarter 2026 earnings call.

  2. November 2026: Headcount reduction from about 140 to 100 full-time employees takes place.

  3. 2027: Company targets core burn breakeven through commercial sales.

Market Landscape

A recent oncologist survey found 75% of respondents view LOQTORZI as standard of care in nasopharyngeal carcinoma, compared with fewer than 35% holding that view for off-label immuno-oncology therapies. That gap suggests the company's commercial position in its approved indication is stronger than that of competing off-label options.

For healthcare workers in the biopharma sector, the restructuring means roughly 40 full-time positions are being eliminated at Coherus Oncology. Job seekers in oncology and clinical roles may find fewer openings at the company in the near term.

The takeaway

Workforce reductions at specialty biopharma companies often signal a pivot toward a narrower set of indications and a path to profitability. Job seekers should watch company pipeline announcements closely when evaluating opportunities in the sector.

What happens next

The company is expected to pursue regulatory discussions with the FDA regarding tagmokitug, though specific timing was not disclosed.

Further reading

Explore more Nursing Jobs coverage for the healthcare workforce context behind this restructuring.